Evan Rajadhyaksha
Research Subjects
Research Interests
Evan Rajadhyaksha has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Asif A. Sharfuddin
Department of Nephrology, Indiana University School of Medicine, Indianapolis, IN
1 shared publication - Daniel J. Fehrenbach
Department of Medicine
1 shared publication - Debora L. Gisch
Indiana University School of Medicine, Indianapolis, USA
1 shared publication - Gerald Chun‐To So
Division of Clinical Pharmacology, Department of Medicine, School of Medicine Indiana University Indianapolis Indiana USA
1 shared publication Jessica Bo Li Lu
Department of Medicine
1 shared publication- Jumar Etkins
Department of Medicine
1 shared publication
Latest Publications
- Open Access
- 18 November 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (1)
Cannabidiol exerts antiinflammatory effects but maintains T effector memory cell differentiation in humans
BACKGROUND: Cannabidiol (CBD) is increasingly used for pain management, including in transplant recipients with limited analgesic options. Its immunomodulatory effects in humans are not well defined at a single-cell level at CBD steady state with concomitant tacrolimus treatment. METHODS: In a phase I ex vivo study, peripheral blood mononuclear cells from 23 participants who received oral CBD (Epidiolex) up to 5 mg/kg twice daily for 11 days were collected before CBD (pre-CBD) and at steady state (post-CBD). Lymphocytes were isolated and stimulated with anti-CD3/CD28 antibodies, with or without tacrolimus (5 ng/mL). Pharmacodynamic responses were assessed using CellTiter-Glo proliferation, single-cell and single-nucleus RNA sequencing, cytokine assays, and flow cytometry. Steady-state plasma concentrations of CBD were quantified via tandem mass spectrometry. RESULTS: We identified an increased proportion of T effector memory (TEM) cells post-CBD (22% increase), which correlated with CBD plasma concentrations ( R = 0.77, P = 0.01). CBD reduced proliferation of T (37% decrease) and CD70 hi B (17% decrease) lymphocytes with additive immunosuppressive effects to tacrolimus. Single-cell RNA sequencing revealed reduced IL2 and TNF signaling and altered receptor-ligand networks in TEM cells. Post-CBD cytokine assays revealed elevated proinflammatory IL-6 protein levels and antiinflammatory IL-10 levels, with reduced TNF-α, LTA, and IL-2. In flow cytometry, the proportion of TEM and TEMRA cells increased post-CBD with tacrolimus. CONCLUSION: CBD exerts mixed immunomodulatory effects in humans, combining antiproliferative and pro- and antiinflammatory responses. Understanding the clinical safety of CBD use is important given the paucity of pain control options available for immunocompromised transplant populations. TRIAL REGISTRATION: ClinicalTrials.gov NCT05490511 FUNDING: NIH/National Center for Complementary and Integrative Health (R01AT011463); NIH/National Institute of General Medical Sciences (NIGMS) (R35GM145383); Intramural Research Program of the NIH; NIH/NIGMS (T32GM008425).
- 18 November 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (1)
Open AccessCannabidiol exerts antiinflammatory effects but maintains T effector memory cell differentiation in humans
BACKGROUND: Cannabidiol (CBD) is increasingly used for pain management, including in transplant recipients with limited analgesic options. Its immunomodulatory effects in humans are not well defined at a single-cell level at CBD steady state with concomitant tacrolimus treatment. METHODS: In a phase I ex vivo study, peripheral blood mononuclear cells from 23 participants who received oral CBD (Epidiolex) up to 5 mg/kg twice daily for 11 days were collected before CBD (pre-CBD) and at steady state (post-CBD). Lymphocytes were isolated and stimulated with anti-CD3/CD28 antibodies, with or without tacrolimus (5 ng/mL). Pharmacodynamic responses were assessed using CellTiter-Glo proliferation, single-cell and single-nucleus RNA sequencing, cytokine assays, and flow cytometry. Steady-state plasma concentrations of CBD were quantified via tandem mass spectrometry. RESULTS: We identified an increased proportion of T effector memory (TEM) cells post-CBD (22% increase), which correlated with CBD plasma concentrations ( R = 0.77, P = 0.01). CBD reduced proliferation of T (37% decrease) and CD70 hi B (17% decrease) lymphocytes with additive immunosuppressive effects to tacrolimus. Single-cell RNA sequencing revealed reduced IL2 and TNF signaling and altered receptor-ligand networks in TEM cells. Post-CBD cytokine assays revealed elevated proinflammatory IL-6 protein levels and antiinflammatory IL-10 levels, with reduced TNF-α, LTA, and IL-2. In flow cytometry, the proportion of TEM and TEMRA cells increased post-CBD with tacrolimus. CONCLUSION: CBD exerts mixed immunomodulatory effects in humans, combining antiproliferative and pro- and antiinflammatory responses. Understanding the clinical safety of CBD use is important given the paucity of pain control options available for immunocompromised transplant populations. TRIAL REGISTRATION: ClinicalTrials.gov NCT05490511 FUNDING: NIH/National Center for Complementary and Integrative Health (R01AT011463); NIH/National Institute of General Medical Sciences (NIGMS) (R35GM145383); Intramural Research Program of the NIH; NIH/NIGMS (T32GM008425).